CLINICAL TRIALS PROFILE FOR IOHEXOL
✉ Email this page to a colleague
All Clinical Trials for IOHEXOL
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00028626 ↗ | Portal Vein Embolization in Treating Patients With Liver Metastases From Primary Colorectal Cancer | Completed | National Cancer Institute (NCI) | Phase 2 | 2001-08-01 | RATIONALE: Embolization blocks blood flow to part of an organ and/or tumor. Blocking the portal vein on one side of the liver may cause the opposite side of the liver to increase in size and decrease the risk of liver failure following surgery. PURPOSE: Phase II trial to study the effectiveness of portal vein embolization in treating patients who have liver metastases from primary colorectal cancer. |
| NCT00028626 ↗ | Portal Vein Embolization in Treating Patients With Liver Metastases From Primary Colorectal Cancer | Completed | Memorial Sloan Kettering Cancer Center | Phase 2 | 2001-08-01 | RATIONALE: Embolization blocks blood flow to part of an organ and/or tumor. Blocking the portal vein on one side of the liver may cause the opposite side of the liver to increase in size and decrease the risk of liver failure following surgery. PURPOSE: Phase II trial to study the effectiveness of portal vein embolization in treating patients who have liver metastases from primary colorectal cancer. |
| NCT00157586 ↗ | Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND) | Completed | Mario Negri Institute for Pharmacological Research | Phase 3 | 2002-02-01 | Diabetes mellitus is one of the most common diseases globally, and is considered epidemic in many developed and newly industrialized nations. Diabetes mellitus represents the single largest cause of end-stage renal disease in the U.S. and Europe. At the same time, the primary cause of early death in diabetic patients are cardiovascular complications. Experimental and clinical studies found that angiotensin converting enzyme inhibitors (ACEi) and calcium channel blockers (CCBs) have a specific renoprotective effect and that this effect can be magnified when the two drugs are used in combination. To formally test this hypothesis we designed the Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND) study, a prospective, randomized, double blind trial aimed to compare the effect of 3 years treatment with the ACEi Delapril (30 mg/day), alone or combined to the CCB Manidipine (10 mg/day), versus conventional (non ACEi, non CCB) therapy on the rate of renal function loss and on the incidence of major cardiovascular events in 342 normo- and micro-albuminuric hypertensive type 2 diabetic patients. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for IOHEXOL
Condition Name
Clinical Trial Locations for IOHEXOL
Trials by Country
Clinical Trial Progress for IOHEXOL
Clinical Trial Phase
Clinical Trial Sponsors for IOHEXOL
Sponsor Name
